Targeted protein degradation (TPD) has emerged as a novel therapeutic method for small molecule drug development to address diseases such as cancer, driven by the aberrant expression of a disease-causing protein.
In the attractive modality of TPD, CMPD Technology is innovative, novel approach to TPD field. CMPD is a technology that utilizes the cellular degradation pathways (ubiquitin-proteasome system, UPS) and biological processes via Chaperone Complex. Chaperones mediates the proper folding, stability and/or activation states of their substrate proteins. Chaperones can also recognize misfolded proteins and direct them towards degradation by the UPS.The ability of chaperones to direct proteins towards the UPS is facilitated by their direct interaction with many different E3 ubiquitin ligases. In terms of the structure, OZ Degrader consist of one moiety which is recognized by Chaperone Complex. This moiety is then chemically covalently linked to a small molecule that recognizes the Target protein. The designed bifunctional molecule promote the interaction of target proteins with components of Chaperone Complex which can direct them toward cellular degradation pathways (UPS), thereby inducing the degradation of the Target protein.
By removing target proteins with different biological processes via Chaperone Complex from other modalities,
OZ Degrader can provide Multiple & Unique Advantages ;
OZ Degrader is consist of one moiety which has novel structure molecule recognized by Chaperone Complex. This moiety is then bound to a small molecule that recognizes the Target protein by Linker (novel structure) in our library, so it is designed to bind to both Target Protein and Chaperone complex and can be designed continuously with expansion.
We have our own chaperone binding molecule with novel structure including a variety of linkers in library and are conducting novel OZ Degraders research in accordance with new target protein study. On the basis of our accumulated technique, optimized drug design for OZ Degraders can be carried out and validated via Artificial Intelligence Technique and we have the ability to derive outstanding drug candidates by developing and verifying based on outcomes of study from our own Research Headquarters Team.
By using our platform technology, we can provide service and/or co-development to potential partners who wan to develop TPD drugs with their novel molecule in development for new target proteins that are causing cancer and other diseases with significant unmet medical needs.